Understanding the mechanism of regulation of the PKGIα and AMPKα2 interaction at the molecular level provides further insights into glomerular disease pathogenesis and novel therapeutic targets for glomerulopathies. This evidence concerns the gene PRKAA2 and lipoprotein glomerulopathy.